US Patent Tri­al and Ap­peal Board to re­con­sid­er Spruce patents around treat­ment for adren­al dis­or­der

The US Patent Tri­al and Ap­peal Board will take a clos­er look at two patents cov­er­ing Spruce Bio­sciences’ ex­per­i­men­tal treat­ment for an adren­al dis­or­der, re­vers­ing re­cent de­ci­sions deny­ing post-grant re­view.

The patents re­late to the use of a CRF1 re­cep­tor an­tag­o­nist to treat con­gen­i­tal adren­al hy­per­pla­sia, a ge­net­ic dis­or­der that af­fects the adren­al glands and can lead to prob­lems with blood pres­sure, blood sug­ar and en­er­gy lev­els. Spruce is de­vel­op­ing its lead can­di­date tildac­er­font as a non-steroidal op­tion for CAH pa­tients, and is ex­pect­ing topline re­sults from two Phase IIb tri­als en­rolling dif­fer­ent groups of pa­tients next year, ac­cord­ing to its lat­est quar­ter­ly re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER